Cue Biopharma
CUE
47 hedge funds and large institutions have $11.9M invested in Cue Biopharma in 2025 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 10 closing their positions.
14% more capital invested
Capital invested by funds: $10.4M → $11.9M (+$1.48M)
0.17% more ownership
Funds ownership: 0.6% → 0.77% (+0.17%)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
4% less funds holding
Funds holding: 49 → 47 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GWMR
GC Wealth Management RIA
Cambridge,
Massachusetts
|
+$2.37M |
| 2 |
BL
Bleichroeder LP
New York
|
+$1.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$620K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$164K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$110K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$193K |
| 2 |
BlackRock
New York
|
-$132K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$117K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$107K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$45.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SG
51
StoneX Group
New York
| – | -$12.8K | -469 | Closed |
|
52
Group One Trading
Chicago,
Illinois
| – | -$12.4K | -452 | Closed |
|
|
TSS
53
Two Sigma Securities
New York
| – | -$9.46K | -346 | Closed |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| – | -$3.53K | -129 | Closed |
|
55
Simplex Trading
Chicago,
Illinois
| – | -$1.71K | -80 | Closed |
|
|
MG
56
Mather Group
Chicago,
Illinois
| – | -$911 | -33 | Closed |
|
|
SFGP
57
Stonebridge Financial Group (Pennsylvania)
Wormleysburg,
Pennsylvania
| – | -$56 | -2 | Closed |
|
CUE Hedge Fund Activity: Q2 2025 in Review
47 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q2 2025, worth a combined $11.9M — up 14% from $10.4M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CUE and 8 opened new positions — a net loss of 2 holders — while 10 trimmed existing stakes and 10 added.
The largest buyer was GC Wealth Management RIA, opening a new position worth an estimated $2.37M. The largest seller was Sigma Planning Corp, cutting an estimated $193K.
- 47 institutional investors held Cue Biopharma (CUE) as of Q2 2025, down from 49 in Q1 2025.
- Funds reported $11.9M of Cue Biopharma stock for Q2 2025, up 14% quarter-over-quarter.
- 8 funds opened new Cue Biopharma positions in Q2 2025 and 10 closed out, a net change of -2 holders.
- The largest Cue Biopharma buyer in Q2 2025 was GC Wealth Management RIA, an estimated $2.37M added.
- The largest Cue Biopharma seller in Q2 2025 was Sigma Planning Corp, an estimated $193K sold.
Based on aggregated 13F filings for Q2 2025.